Reproducibility of SELDI spectra across time and laboratories

Cancer Informatics

Volumn 10, Issue , 2011, Pages 45-64

  Diao, Lixia ^a   Clarke, Charlotte H ^a   Coombes, Kevin R ^a   Hamilton, Stanley R ^a   Roth, Jack ^a   Mao, Li ^b   Czerniak, Bogdan ^a   Baggerly, Keith A ^a   Morris, Jeffrey S ^a   Fung, Eric T ^c   Bast Jr , Robert C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^c CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

Analysis of variance reproducibility SELDI; Mass spectrometry wavelet

Indexed keywords

BIOLOGICAL MARKER;

ANALYSIS OF VARIANCE; ARTICLE; CALIBRATION; CONTROLLED STUDY; INFORMATION PROCESSING; LABORATORY TEST; PROTEIN MICROARRAY; REPRODUCIBILITY; SERUM; SIGNAL NOISE RATIO; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME;

EID: 79952953328     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S6438     Document Type: Article

References (52)

1. Tumblin A, Tailor A, Hoehn, et al. Apolipoprotein A-I and serum amyloid a plasma levels are biomarkers of acute painful episode in patients with sickle cell disease. Haematologica. April 7 2010. [Epub ahead of print].
2. MacGregor G, Gray RD, Hilliard TN, et al. Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros. 2008 p 7;(5):352-8.
3. Yang S, Xu L, Wu HM. Rapid multiplexed genotyping for hereditary thrombophilia by SELDI- TOF mass spectrometry. Diagn Mol Pathol. 2010; 19(1):54-61.
4. De Young LX, Bella AJ, O'Gorman DB, Gan BS, Lim KB, Brock GB. Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med. 2010;7(1 Pt 1):99-106.
5. Simonsen AH, McGuire J, Podust VN, et al. Identification of a novel panel of cerebrospinal fluid biomarkers of Alzeheimer's disease. Neurobiol Aging. 2008;29(7):961-8.
6. Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura uing surface enhanced laser desorption/ ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost. 2006;4(2):333-8.
7. Wilson AM, Kimura E, Harada RK, et al. b2-Microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation. 2007;116(12):1396-403.
8. Fan Y, Wang J, Yang Y, et al. Detection and identification of potential biomarkers of breast cancer. J Cancer Res Clin Oncol. Mar 17 2010. [Epub ahead of print].
9. Shi L, Zhang J, Wu P, et al. Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci. Mar 16 2009;7:7.
10. Caron J, Mange A, Guillot B, Solassol J. Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol. Sep 2009;135(9):1257-64.
11. Wei YS, Zheng YH, Liang WB, et al. Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis. Cancer. Feb 1 2008; 112(3):544-51.
12. Yang SY, Xiao XY, Zhang WG, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. Jul 20 2005;5:83.
13. Lu HB, Zhou JH, Ma YY, et al. Five serum proteins identified using SELDITOF- MS as potential biomarkers of gastric cancer. Jpn J Clin Oncol. Apr 2010;40(4):336-42.
14. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. Aug 15 2004;64(16):5882-90.
15. Fan Y, Shi L, Liu Q, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer. Sep 28 2009:8-79.
16. Liu M, Li CF, Chen HS, et al. Differential expression of proteomics models of colorectal cancer, colorectal benign disease and healthy controls. Proteome Sci. Mar 25 2010;8(1):16.
17. Saito Y, Oba N, Nishinadagawa S, et al. Identification of beta2- microgloblin as a candidate for early diagnosis of imaging- invisible hepatocellular carcinoma in patient with liver cirrhosis. Oncol Rep. May 2010;23(5): 1325-30.
18. Kakehashi A, Kato A, Inoue M, et al. Cytokeratin 8/18 as a new marker of mouse liver preneoplastic lesions. Toxicol Appl Pharmacol. Jan 1 2010; 242(1):47-55.
19. Guo J, Wang W, Liao P, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. Dec 2009;100(12): 2292-301.
20. Vermaat JS, Vander Tweel I, Mehra N, et al. Two-protein signature of novel serological markers apolipoprotein-A1 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
21. Bouamrani A, Ramus C, Gay E, et al. Increased phosphorylation of vimentin in noninfiltrative meningiomas. PLoS One. Feb 16 2010;5(2):e9238.
22. Al-Ruwaili JA, Larkin SE, Zeidan BA, et al. Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis. Cancer Genomics Proteomics. Mar-Apr 2010;7(2):93-103.
23. Han M, Liu Z, Yu J, Zheng S. Identification of candidate molecular markers predicting chemotherapy resistance in non-small cell lung cancer. Clin Chem Lab Med. Mar 26 2010. [Epub ahead of print].
24. He J, Shen D, Chung DU, et al. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int J Oncol. Oct 2009;35(4): 683-92.
25. Dalenc F, Doisneau-Sixou SF, Allal BC, et al. Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. Clin Cancer Res. Feb 15 2010;16(4):1264-71.
26. Petrik V, Saadoun S, Loosemore A, et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. Apr 2008;54(4): 713-22.
27. Grizzle WE, Semmes OJ, Basler J, et al. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology.
28. McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. Jan 2008;54(1):53-60.
29. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. Jan 2005;51(1):102-12.
30. Linke T, Doraiswamy S, Harrison EH. Rat plasma proteomics: effects of abundant protein depletion on proteomic analysis. J Chromatogr B Analyt Technol Biomed Life Sci. Apr 2007 15;849(1-2):273-81.
31. Andersen JD, Boylan KL, Xue FS, et al. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis. Jan 2010;31(4): 599-610.
32. Orvisky E, Drake SK, Martin BM, et al. Enrichment of low molecular weight fration of serum for MS analysis of peptides associated with hepatocellular carcinoma. Proteomics. May 2006;6(9):2895-902.
33. Zhou J, Trock B, Tsangaris RN, et al. A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. Breast Cancer Res Treat. Nov 10 2009. [Epub ahead of print].
34. Jansen C, Hebeda KM, Linkels M, et al. Protein profiling of B-cell lymphomas using tissue biopsies: A potential tool for small samples in pathology. Cell Oncol. 2008;30(1):27-38.
35. Ward DG, Nyangoma S, Joy H, et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. Jun 16 2008;6:19.
36. Shirai Y, Sogawa K, Yamaguchi T, et al. Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas. Hepatogastroenterology. Sep-Oct 2008;55(86-87):1824-9.
37. Melle C, Ernst G, Winkler R, et al. Proteomic analysis of human papillomavirus-related orgal squamous cell carcinoma: identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics. Apr 2009;9(8):2193-201.
38. Sun W, Ye Z, Mi Z, Shi T, Han C, Guo S. A comparative study on proteomics between LNCap and DU145 cells by quantitative detection and SELDI analysis. J Hauzhong Univ Sci Technolog Med Sci. Apr 2008;28(2):174-8.
39. Shintani S, Hamakawa H, Ueyama Y, Hatori M, Toyoshima T. Identification of a truncated cystatin SA-I as a saliva biomarker for oral squamous cell carcinoma using the SELDI ProteinChip platform. Int J Oral Maxillofac Surg. Jan 2010;39(91):68-74.
40. Albrethsen J, Bøgebo R, Olsen J, Raskov H, Gammeltoft S. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum. Clin Chem Lab Med. 2006;44(10):1243-52.
41. Timms JF, Arslan-Low E, Gentry-Maharaj A, et al. Preanalytic influence of sample handling on SELDI-TOF serum protein profiles. Clin Chem. Apr 2007;53(4):645-56.[Epub Feb 15 2007].
42. Rai AJ, Stemmer PM, Zhang Z, et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics. Aug 2005;5(13):3467-74.
43. Liggett WS, Barker PE, Semmes OJ, Cazares LH. Measurement reproducibility in the early stages of biomarker development. Disease Markers. 2004;20:295-307.
44. Coombes KR, Tsavachidis S, Morris JS, Baggerly KA, Hung MC, Kuerer HM. Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics. 2005;5: 4107-17.
45. Morris JS, Coombes KR, Koomen JM, Baggerly KA, Kobayashi R. Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics. 2005;21:1764-75.
46. R Development Core Team. R; A language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2004. ISBN 3-900051-07-0.
47. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-Plus, New York, Springer-Verlag, 2000. ISBN 0-387-98957-0.
48. Johnson KL, Mason CJ, Muddiman DC, Eckel JE. Analysis of the low molecular weight fraction of serum by LC-dual ESI-FT-ICR mass spectrometry: precision of retention time, mass, and ion abundance. Anal Chem. 2004;76:5097-103.
49. Hong H, Dragan Y, Epstein J, et al. Quality control and quality assessment of data from surface enhanced laser desorption/ionization (SELDI) time of flight (TOF) mass spectrometry. BMC Bioinformatics. 2005;6(Suppl 2):S5.
50. Semmes OJ, Cazares LH, Ward MD, et al. Discrete serum protein signatures discriminate between human retrovirus associated hematologic and neurologic disease. Leukemia. 2005;19:1229-38.
51. Forshed J, Pernemalm M, Seng Tan C, et al. Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia. J Proteome Res. 2008; 7(6):2332-41.
52. Du P, Kibbe W, Lin S. Improved peak detection in mass spectrum by incorporating continuous wavelet transform-based pattern matching. Bioinformatics. 2006;22(17):2059-65.